Plan B Decision Mobilizes House Members To Seek FDA Integrity Review
This article was originally published in The Tan Sheet
Executive Summary
A House bill directing FDA to conduct a formal review of the process leading up to its decision to designate as "not approvable" the Rx-to-OTC switch application for the Plan B emergency contraceptive was introduced by Rep. Carolyn Maloney (D-N.Y.) on May 14
You may also be interested in...
House Democrats Take Plan B Battle To Appropriations Bill
An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13
House Democrats Take Plan B Battle To Appropriations Bill
An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13
House Democrats Take Plan B Battle To Appropriations Bill
An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13